Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data.

Mimidis K, Papadopoulos VP, Elefsiniotis I, Koliouskas D, Ketikoglou I, Paraskevas E, Kanatakis S, Chrysagis D, Dalekos GN, Tzathas C, Protopapas A, Gigi E, Tsianos E, Kartalis G.

J Gastrointestin Liver Dis. 2006 Sep;15(3):213-9.

3.

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

Villa E, Cammà C, Di Leo A, Karampatou A, Enea M, Gitto S, Bernabucci V, Losi L, De Maria N, Lei B, Ferrari A, Vukotic R, Vignoli P, Rendina M, Francavilla A.

J Viral Hepat. 2012 Sep;19(9):640-9. doi: 10.1111/j.1365-2893.2012.01593.x. Epub 2012 Mar 15.

PMID:
22863268
4.

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.

J Viral Hepat. 2005 May;12(3):283-91.

PMID:
15850469
5.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

6.

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R, Al-Nakib B.

Am J Gastroenterol. 2004 Sep;99(9):1733-7.

PMID:
15330911
7.

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.

Pharmacoeconomics. 2004;22(4):257-65.

PMID:
14974875
8.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK.

Lancet. 2001 Sep 22;358(9286):958-65.

PMID:
11583749
9.

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T.

Dig Dis Sci. 2005 May;50(5):970-5.

PMID:
15906777
10.

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team..

JAMA. 2004 Dec 15;292(23):2839-48.

PMID:
15598915
11.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
12.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.

PMID:
15307866
13.
14.

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.

Benetti G, Borzio M, Ramella G, Bellati G, Fargion S, Colombo A, Croce G, Iamoletti C, Balzola F, Rizzetto M; GEL (Gruppo Epatologico Lombardo)..

Intern Emerg Med. 2006;1(2):113-8.

PMID:
17111783
15.

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.

Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, Falco V, Quer J, Ocaña I, Ruiz I, Buti M, Pahissa A, Esteban R, Guardia J.

J Viral Hepat. 2007 Apr;14(4):228-38.

PMID:
17381714
16.

Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.

Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

J Gastroenterol Hepatol. 2007 May;22(5):645-52. Erratum in: J Gastroenterol Hepatol. 2007 May;22(5):768.

PMID:
17444850
18.

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M.

Hepatology. 2007 Dec;46(6):1732-40.

PMID:
17943989
19.

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C; French multicenter study group..

J Viral Hepat. 2006 Dec;13(12):811-20.

PMID:
17109680
20.

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.

Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, Rammert C, Gonvers JJ, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL; Swiss Association for the Study of the Liver (SASL)..

J Viral Hepat. 2006 Jul;13(7):457-65.

PMID:
16792539

Supplemental Content

Support Center